EMAGLIFLOZIN L 10/5MG

EMAGLIFLOZIN L – Dual Action Diabetes Control for Better Health

EMAGLIFLOZIN L is a combination medicine that combines Empagliflozin, an advanced SGLT2 inhibitor, with Linagliptin, a DPP-4 inhibitor. This dual-action formula helps adults with Type 2 Diabetes Mellitus (T2DM) achieve superior blood sugar control by targeting different pathways of glucose management.

Empagliflozin works by helping the kidneys remove excess glucose through urine, while Linagliptin increases incretin levels, which in turn stimulates insulin release and reduces glucose production. Together, they provide powerful and convenient once-daily diabetes control, with added benefits for weight management and heart health.

✅ Key Benefits:

• Provides better blood sugar control through dual mechanisms

• Reduces risk of heart-related complications in diabetic patients

• May help with weight management and lower blood pressure

• Convenient once-daily oral tablet

• Well-tolerated with minimal risk of hypoglycemia when used as prescribed